CuraVac 1A
Stephane Huberty
Founder
A medical doctor and biotech entrepreneur with over 30 years of experience in healthcare and innovation. Driven by both clinical expertise and personal experience with Myasthenia Gravis, he founded CuraVac to develop targeted immunotherapies for autoimmune diseases.
https://www.linkedin.com/in/stephane-huberty-25058796/
Jean-Paul Prieels
Executive director
Former SVP of R&D at GSK Vaccines, where he played a pivotal role in developing multiple commercial vaccines.
https://www.linkedin.com/in/jean-paul-prieels-4423257/
Nicolas Havelange
COO
A biopharmaceutical manufacturing expert with a track record in vaccine development.
https://www.linkedin.com/in/nicolas-havelange-6914a51/
Olivier Stevens
Advisor
Veterinary doctor who followed the development of CuraVac as an early investor and brings his expertise in family veterinary practice in small animals.
https://www.linkedin.com/in/olivier-stevens-044339158/
Leone Flynn
Executive director
Experienced SME manager who has been the Chief Administrative Officer at CuraVac since its inception in 2002.
https://www.linkedin.com/in/leone-flynn-a87818/
Mattieu André
CFO
Bioengineer with a finance degree and 15 years of experience in corporate finance.
https://www.linkedin.com/in/andrematthieu/
Raise summary
| Crowd investments | €0 |
| Committed by others | €650,000 |
| Amount raised | €650,000 |
| Minimum round | €200,000 |
| Maximum round | €1,625,000 |
| Shares in the company (total round) | 6.341% |
| Pre-money valuation | €24,000,000 |
| Post-money valuation min. | €24,200,000 |
| Post-money valuation max. | €25,625,000 |